Two more patients die in trial of Juno's JCAR015

By Gareth Macdonald contact

- Last updated on GMT

Two more patients die in trial of Juno's JCAR015

Related tags: Leukemia

Two more patients have died during a trial of Juno Therapeutics’ candidate white blood cell cancer therapy, JCAR015.

Juno announced the deaths today, explaining that both subjects died as a result of cerebral edema, which is a swelling in the brain caused by excess fluid.

The Seattle biotech also said it has halted the trial – known as ROCKET - while it investigates the incidents.

A spokesman told us "The two patients who died earlier this week did not receive fludarabine. They were on a pre-conditioning regimen of cyclophosphamide only​."

Earlier deaths

In July​ the US FDA ordered Juno to halt the same trial following the death of three patients.

All three patients also died as a result of cerebral edema.

At the time Juno attributed the deaths to chemotherapies the patients received in addition to JCAR015, rather than to the therapy itself.

The firm was allowed to restart the trial a few days later​ after it removed one of the chemotherapeutic agents – fludarabine – from the protocol.

Rocket trial

The trial is a Phase II study examining JCAR015 in the treatment of patients suffering relapsed or refractory B cell acute lymphoblastic leukemia (ALL).

JCAR015 consists of an infusion of the patient's own T cells that have been genetically modified to express a chimeric antigen receptor (CAR) that will bind to leukemia cells that express the CD19 protein on the cell surface. 

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars